About Us
News
Products
Technolongy Platform
Investors
Contact Us
中文
EN
NEWS
Business Milestones
Patents
ALL
無列表圖
Business Milestones
11.17
2024
TAHO Pharmaceuticals Initiates U.S. Phase III Clinical Trial of TAH3311 Antithrombotic Oral Dissolving Film, Dosing First Subjects
無列表圖
Patents
04.21
2021
TAHO's TAH9922 Atomoxetine oral solution product patent obtained a US patent license.
無列表圖
Business Milestones
11.20
2019
TAHO's pediatric ADHD Oral Liquid granted exclusive U.S. sales rights to Hyloris
無列表圖
Patents
11.29
2017
TAHO obtained U.S. patent approval for TAH9901 methylphenidate transdermal patch, a transdermal ADHD treatment for pediatric ADHD.
無列表圖
Patents
09.01
2017
TAHO obtained U.S. patent approval for TAH9922 Atomoxetine oral solution, a child friendly ADHD mediation.
無列表圖
Business Milestones
08.16
2017
TAHO obtained approval for TAH4411 in Japan, a first anti-emetic oral dissolving film for chemotherapy in Japan.
中文
EN
About Us
News
Products
Technolongy Platform
Investors
Contact Us
ADD
3F., No. 550, Ruiguang Road, Neihu District, Taipei, 11492, Taiwan
TEL
+886-2-2659-8515
MAIL
info@tahopharma.com
© 2023 TAHO Pharmaceuticals Ltd. All rights reserved.
Design ibest
Verification
Click the numbers in sequence.
Change
